„Surgery only“ reicht nicht aus: Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase

S. C. Schmid; J. Lewerich; M. Retz; Claus Rödel

doi:10.1007/s00120-022-01963-9

„Surgery only“ reicht nicht aus: Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase

Translated title of the contribution: “Surgery only” is not enough: potential of multimodal therapy in urothelial bladder carcinoma

S. C. Schmid
, J. Lewerich
, M. Retz
, Claus Rödel

Department of Urology

Technical University of Munich
Klinikum der J. W. Goethe-Universität

Research output: Contribution to journal › Review article › peer-review

Abstract

Radical cystectomy is the standard treatment for muscle invasive bladder cancer. Using perioperative cisplatin-based chemotherapy, 5‑year overall survival rates are 5% higher with neoadjuvant chemotherapy compared to local therapy alone. New multimodal concepts have been developed to improve oncologic efficacy and to reduce treatment-related morbidity. Perioperative use of checkpoint inhibitors aims at improving efficacy, while bladder-preserving concepts try to avoid cystectomy in good responders. This article reviews new developments in radioimmunotherapy and perioperative combination therapies as well as bladder-preserving concepts like trimodal bladder therapy.

Translated title of the contribution	“Surgery only” is not enough: potential of multimodal therapy in urothelial bladder carcinoma
Original language	German
Pages (from-to)	1332-1340
Number of pages	9
Journal	Urologie
Volume	61
Issue number	12
DOIs	https://doi.org/10.1007/s00120-022-01963-9
State	Published - Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-022-01963-9

Cite this

@article{5962fa35b76a475d85445e4334036a80,

title = "„Surgery only“ reicht nicht aus: Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase",

abstract = "Radical cystectomy is the standard treatment for muscle invasive bladder cancer. Using perioperative cisplatin-based chemotherapy, 5‑year overall survival rates are 5\% higher with neoadjuvant chemotherapy compared to local therapy alone. New multimodal concepts have been developed to improve oncologic efficacy and to reduce treatment-related morbidity. Perioperative use of checkpoint inhibitors aims at improving efficacy, while bladder-preserving concepts try to avoid cystectomy in good responders. This article reviews new developments in radioimmunotherapy and perioperative combination therapies as well as bladder-preserving concepts like trimodal bladder therapy.",

keywords = "Checkpoint inhibitors, Immune-modulating therapy, Perioperative treatment, Programmed cell death ligand 1, Radioimmunotherapy",

author = "Schmid, \{S. C.\} and J. Lewerich and M. Retz and Claus R{\"o}del",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2022",

month = dec,

doi = "10.1007/s00120-022-01963-9",

language = "Deutsch",

volume = "61",

pages = "1332--1340",

journal = "Urologie",

issn = "2731-7064",

publisher = "Springer Medizin",

number = "12",

}

TY - JOUR

T1 - „Surgery only“ reicht nicht aus

T2 - Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase

AU - Schmid, S. C.

AU - Lewerich, J.

AU - Retz, M.

AU - Rödel, Claus

PY - 2022/12

Y1 - 2022/12

N2 - Radical cystectomy is the standard treatment for muscle invasive bladder cancer. Using perioperative cisplatin-based chemotherapy, 5‑year overall survival rates are 5% higher with neoadjuvant chemotherapy compared to local therapy alone. New multimodal concepts have been developed to improve oncologic efficacy and to reduce treatment-related morbidity. Perioperative use of checkpoint inhibitors aims at improving efficacy, while bladder-preserving concepts try to avoid cystectomy in good responders. This article reviews new developments in radioimmunotherapy and perioperative combination therapies as well as bladder-preserving concepts like trimodal bladder therapy.

AB - Radical cystectomy is the standard treatment for muscle invasive bladder cancer. Using perioperative cisplatin-based chemotherapy, 5‑year overall survival rates are 5% higher with neoadjuvant chemotherapy compared to local therapy alone. New multimodal concepts have been developed to improve oncologic efficacy and to reduce treatment-related morbidity. Perioperative use of checkpoint inhibitors aims at improving efficacy, while bladder-preserving concepts try to avoid cystectomy in good responders. This article reviews new developments in radioimmunotherapy and perioperative combination therapies as well as bladder-preserving concepts like trimodal bladder therapy.

KW - Checkpoint inhibitors

KW - Immune-modulating therapy

KW - Perioperative treatment

KW - Programmed cell death ligand 1

KW - Radioimmunotherapy

UR - https://www.scopus.com/pages/publications/85143511419

U2 - 10.1007/s00120-022-01963-9

DO - 10.1007/s00120-022-01963-9

M3 - Übersichtsartikel

AN - SCOPUS:85143511419

SN - 2731-7064

VL - 61

SP - 1332

EP - 1340

JO - Urologie

JF - Urologie

IS - 12

ER -

„Surgery only“ reicht nicht aus: Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this